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In Brief
The T cell allorecognition pathways
governing rejection of organ allografts are
poorly understood. Using a model of
chronic heart graft rejection, Ali et al.
show that continual presentation of MHC
class I allopeptide drives late division in
the responding alloreactive CD4 T cell
population, resulting in a markedly
augmented maintenance phase.
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MHC alloantigen is recognized by two pathways:
‘‘directly,’’ intact on donor cells, or ‘‘indirectly,’’ as
self-restricted allopeptide. The duration of each
pathway, and its relative contribution to allograft
vasculopathy, remain unclear. Using a murine
model of chronic allograft rejection, we report that
direct-pathway CD4 T cell alloresponses, as well
as indirect-pathway responses against MHC class
II alloantigen, are curtailed by rapid elimination of
donor hematopoietic antigen-presenting cells. In
contrast, persistent presentation of epitope resulted
in continual division and less-profound contraction
of the class I allopeptide-specific CD4 T cell popu-
lation, with approximately 10,000-fold more cells
persisting than following acute allograft rejection.
This expanded population nevertheless displayed
sub-optimal anamnestic responses and was un-
able to provide co-stimulation-independent help
for generating alloantibody. Indirect-pathway CD4
T cell responses are heterogeneous. Appreciation
that responses against particular alloantigens domi-
nate at late time points will likely inform develop-
ment of strategies aimed at improving transplant
outcomes.
INTRODUCTION
Chronic rejection, leading to late graft loss, remains the major
challenge for solid organ transplantation. T cells play a critical
role in the development of chronic rejection (Ali et al., 2013; Libby
and Pober, 2001), but it is not clear whether the early T cell
response following transplantation is sufficient to mediate
chronic rejection or, as seems more likely, persistent alloan-
tigen-driven T cell responses are required over a longer period
of time.
CD4 T cells recognize alloantigen through two distinct path-
ways. In the ‘‘direct pathway,’’ alloreactive T cells recognize
intact donor MHC molecules presented on the surface of
donor antigen-presenting cells (APCs), whereas in the ‘‘indirect
pathway,’’ T cells recognize major, and minor, histocompatibility1232 Cell Reports 14, 1232–1245, February 9, 2016 ª2016 The Authoantigens that have been acquired by recipient APCs, processed
and presented as self-MHC-restricted peptides (Ali et al., 2013;
Jiang et al., 2004). The relative contribution of these pathways to
chronic graft rejection remains unclear (Benichou, 1999; Gould
and Auchincloss, 1999; Nadazdin et al., 2011). It has generally
been assumed that direct-pathway CD4 T cell alloresponses
are short lived due to rapid destruction of donor APCs following
transplantation. Consequently, chronic rejection is considered to
be largely mediated by indirect-pathway CD4 T cell responses
(Baker et al., 2001; Ciubotariu et al., 1998; Haynes et al., 2012;
Hornick et al., 2000; Safinia et al., 2010). However, late direct-
pathway responses have been reported in primate studies (Na-
dazdin et al., 2011), possibly reflecting upregulated expression
of MHC class II on allograft endothelium. Similarly, the indirect
CD4 T cell allorecognition pathway is generally regarded as a
single entity but is instead presumably a culmination of multiple
responses against potentially every disparate alloantigen ex-
pressed by the graft. Given that these antigens are likely to be
expressed at different concentrations in the graft and, in the
case of MHC class II, predominantly expressed on the hemato-
poietic components of the graft, it is plausible that the duration
and strength of indirect-pathway responses differ depending
on the target alloantigen. This concept has yet to be examined
definitively.
Here, we show in a murine model of chronic allograft rejection
that direct-pathway CD4 T cell responses are short lived but also
that indirect-pathway responses are heterogeneous and vary
markedly according to target antigen. Whereas those directed
against MHC II allopeptide decline rapidly after transplant, the
persistent presentation of immunogenic target epitope provokes
continued division of MHC class I allopeptide-specific CD4
T cells and results in a markedly augmented late maintenance
phase. Anamnestic function in this expanded population is
nevertheless sub-optimal. The implications of our findings to
late graft rejection are discussed.
RESULTS
Experimental Approach and Characterization of
Transplant Model
To examine the CD4 T cell allorecognition pathways active at
early and late time points after transplantation, a donor strain
(bm12.Kd.IE) was created that differed from the C57BL/6 recip-
ient strain at the I-Abm12 and I-Ed MHC class II and H-2Kd MHCrs
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B Figure 1. Characterization of MHC-Mis-
matched Murine Model of Chronic Heart
Allograft Vasculopathy
(A) B6.Kd, bm12, and ABOIE mice were inter-
crossed to create a ‘‘bm12.kd.IE’’ donor strain that
differed from the C57BL/6 recipient strain at
the classical MHC class I H-2K and MHC class II
I-A and I-E loci, enabling direct-pathway CD4
T cell alloimmunity to be assessed by adoptive
transfer of CFSE-labeled, TCR-transgenic ABM
CD4 T cells.
(B) I-Ab-restricted indirect pathway CD4 T cell re-
sponses against MHC class I H-2Kd, MHC class II
IE, and minor H-Y dby antigen could be similarly
assessed by transfer of TCR-transgenic TCR75,
Tea, and Marilyn CD4 T cells, respectively.
(C and D) Whereas syngeneic C57BL/6 heart
grafts survive indefinitely, bm12.kd.IE heart allo-
grafts are rejected slowly by C57BL/6 recipients
(C) with development of progressive allograft
vasculopathy (D): representative photomicro-
graphs of elastin van-Gieson-stained paraffin
sections depicting typical fibroproliferative arterial
intimal thickening observed in rejecting heart al-
lografts (scale bars, 100 mm).
(E–H) Rejection is associated with development of
germinal centers (E), class-switched anti-nuclear
autoantibody (F), and anti H-2Kd (G) and anti-I-E
(H) alloantibody responses.
*p < 0.05, **p < 0.01, and ***p < 0.001 (Kaplan-
Meier log rank analysis in C, Mann-Whitney test in
D and E, and two-way ANOVA in F–H). Data
represent mean and SEM of n = 7 mice per group.class I loci (Figure 1A), enabling direct and indirect CD4 T cell
recipient alloresponses to be assessed by adoptive transfer
of populations of TCR-transgenic CD4 T cells with precise
specificity for alloantigen. Following transplantation of male
bm12.Kd.IE hearts into female C57BL/6 recipients, direct-
pathway CD4 T cell responses against MHC class II I-Abm12 allo-
antigen were assessed by quantifying division of adoptively
transferred ABM CD4 T cells. Indirect-pathway CD4 T cell re-
sponses against I-Ab-restricted MHC class I H-2Kd alloantigen,
MHC class II I-E alloantigen, and minor male H-Y alloantigen
were assessed by division of adoptively transferred TCR75,
TEa, and Marilyn CD4 T cells, respectively (Figure 1B): theseCell Reports 14, 1232–1245,T cell clones do not recognize donor
I-Abm12-restricted alloantigen (Figure S1).
Bm12.Kd.IE heart allografts were not re-
jected acutely (Figure 1C) but showed
progressive allograft vasculopathy (Fig-
ure 1D), with rejection characterized by
development of germinal center (GC)
anti-class I (H-2Kd) and anti-class II (I-E)
alloantibody and anti-nuclear autoanti-
body responses (Figures 1E–1H).
Heterogeneity of Indirect-Pathway
CD4 T Cell Responses
Responses of the transferred allospecific
CD4 T cell clones to the heart allograftwere quantified by carboxyfluorescein succinimidyl ester
(CFSE) division profiles (Figure S2) but with the modification
that CD4 T cell clones were transferred early, at transplantation,
or late on day 28 after transplant (to measure CD4 T cell allores-
ponses during the first and fifth week, respectively). We
reasoned that division of the transferred CD4 T cells would be
contingent upon expression of, and stimulation by, the appro-
priate alloantigen epitope (Obst et al., 2005). In the first week
after heart transplantation, robust indirect-pathway CD4 T cell
responses were detected against H-2Kd MHC class I, I-E MHC
class II, and H-Y alloantigen (Figure 2A). At 5 weeks, the re-
sponses against MHC class I allopeptide and H-Y antigenFebruary 9, 2016 ª2016 The Authors 1233
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were preserved, albeit the anti-H-Y response was slightly
attenuated. In contrast, the anti-I-E response was undetectable
(Figure 2A).
Indirect Alloresponses against MHC Class II Alloantigen
Are Limited by Antigen Availability
Further experiments revealed that the anti-I-E indirect-pathway
response decayed by week 2 (Figure 2B). To test the hypothesis
that this reflected elimination of donor hematopoietic cells (the
likely major source of MHC class II alloantigen), anti-MHC class
II indirect-pathway responses were evaluated following trans-
plantation with bm12.kd.IE hearts from donors that had either
been subject to lethal irradiation or depleted of the dendritic
cell (DC) fraction. Both approaches resulted in marked attenua-
tion of the early (week 1) anti-class II indirect-pathway CD4 T cell
response (Figure 2C). In contrast, adoptive transfer of donor DCs
into C57BL/6 recipients of a bm12.Kd.IE heart allograft at a late
time point (day 28) after transplantation partially restored the late
TEa CD4 T cell response (Figure 2D). Parallel experiments, in
which DCs from recipients of bm12.kd.IE heart grafts were
stained with ‘‘YAe’’ clonotypic antibody, confirmed that expres-
sion of I-E peptide epitope for TEa CD4 T cell recognition
mirrored the presence and survival of the donor hematopoietic
fraction (Figure 2E). As expected, recipient hematopoietic cells
were also required for TEa CD4 T cell responses, reflecting their
role as professional APCs for I-Ab-restricted allopeptide presen-
tation (Figure 2C). Additional experiments incorporating T- and
B-cell-deficient Rag2/ mice as recipients of bm12.kd.IE heart
allografts surprisingly revealed that the rapid destruction of
donor hematopoietic cells by C57BL/6 recipients was not a
consequence of innate NK cell recognition but was instead
mediated by C57BL/6 adaptive alloresponses (Figure S3).
AlthoughMHCclass II is generally not thought to be expressed
by resting murine endothelium, activation-induced upregulation,
as typically occurs within the endothelium of rejecting allografts,
has been described (Hasegawa et al., 1998; Milton and Fabre,
1985). In support, I-E MHC class II was detectable on cultured
bm12.Kd.IE endothelial cells and was evident on immunohisto-
chemical staining of bm12.Kd.IE heart allografts explanted at
1 week (Figure 3).Figure 2. Heterogeneity of Indirect-Pathway CD4 T Cell Responses
(A) Following transplantation of female C57BL/6 recipients with a male bm12.Kd
MHC class I H-2Kd, MHC class II I-E, and minor H-Y antigen were assessed by
division) of CFSE-labeled TCR75, Tea, and Marilyn CD4 T cells, respectively, tra
(B) Whereas CFSE-labeled TEa CD4 T cells proliferate robustly when transferred
division is observed when TEa CD4 T cells are transferred 1 week later.
(C) Division profiles of TEa CD4 T cells transferred to C57BL/6 recipients at transp
either the donor or recipient mice depleted of B cells and/or DCs. Division profi
bm12.Kd.IE heart allograft are shown. Profiles of transferred naive TEa CD4 T ce
(D) Also shown is division of naive TEa CD4 T cells transferred 5 weeks after tran
before TEa transfer. Statistical comparison is to untreated group.
(E) YAe clonotypicantibodywasused to identify I-Ab-restricted I-Epeptide epitope o
naive C57BL/6 mice (dotted), naive BALB/c x C57BL/6 F1 (CB6F1) mice (dashed),
plantation (solid) is shown. (Right panel) Comparative YAe staining of splenicDCs fr
bm12.Kd.IE heart allografts; C57BL/6 recipients 2 weeks after bm12.Kd.IE heart
transplantation is shown (DCs purified from C57BL/6 recipients 5 days after bm12
*p < 0.05, **p < 0.01, and ***p < 0.001 (Mann-Whitney test in A, C, and D). Data are
(A, C, and D; mean and SEM of n = 5 mice per group).
Cell RThe rapid decline of the anti-MHC class II indirect-pathway
CD4 T cell response is therefore surprising but may reflect tran-
sient expression of MHC class II on graft parenchymal cells;
memory TEa CD4 T cells (Figure S4), which would be expected
to respond to target epitope even when encountered in the
absence of costimulatory ligands, proliferated more robustly
than naive cells when transferred into C57BL/6 recipients of
bm12.Kd.IE heart allografts at the time of transplant but failed
to proliferate when transferred at late time points (Figure 2D).
Persistent Indirect-Pathway CD4 T Cell Activation from
Graft Parenchymal Expression of MHC Class I
Unlike anti-MHC class II indirect-pathway responses, donor DC
depletion or donor irradiation made little impact on CD4 T cell
allorecognition of H-2Kd allopeptide (Figure 4A). To confirm
that late anti-MHC class I indirect-pathway CD4T cell responses
were due to recognition of MHC class I alloantigen on graft
parenchyma, bm12.Kd.IE bone marrow chimeric mice were
created in which H-2Kd expression was restricted to the hemato-
poietic lineage, whereas the graft parenchyma expressed the
I-Abm12 and I-E alloantigens (Figure 4B). Heart grafts from these
mice provoked only a transient anti-MHC class I indirect-
pathway response (Figure 4C). Similarly, BALB/c heart allografts,
which are rejectedwithin 7 days in C57BL/6 recipients andwhich
presumably do not shed alloantigen thereafter, did not elicit indi-
rect-pathway responses against MHC class I at late time points
(Figure 4D).Moreover, treatment of C57BL/6 recipients with anti-
CD154 mAb at transplant with a BALB/c heart allograft, a proto-
col that prevents acute graft rejection but nevertheless results in
chronic graft damage (Figure S5; Larsen et al., 1996), restored
late TCR75 CD4 T cell responses, whereas indirect-pathway
responses against MHC class II antigen were still only short lived
(Figure 4D).
Direct-Pathway CD4 T Cell Responses Are Short Lived
and Curtailed by Innate and Adaptive Alloimmunity
The longevity of direct-pathway CD4 T cell allorecognition was
assessed in C57BL/6 recipients of bm12.Kd.IE heart grafts
by adoptive transfer of I-Abm12 reactive ABM CD4 T cells.
As for anti-MHC class II indirect-pathway CD4 T cells, direct.IE heart allograft, indirect pathway CD4 T cell responses against mismatched
quantifying division (expressed as percentage of cells undergoing at least one
nsferred at either transplantation or 5 weeks later.
at transplantation of a C57BL/6 recipient with a bm12.Kd.IE heart allograft, no
lantation with bm12.Kd.IE heart allografts, with the donors lethally irradiated or
les following transfer of memory TEa CD4 T cells to C57BL/6 recipients of a
lls are replicated from (A) for comparison.
splantation to a C57BL/6 recipient that received bm12.Kd.IE BMDCs the day
npurifiedDCs. (Left panel)Overlay histogramofYAestainingof splenicDCs from
and DCs purified from C57BL/6 recipients 5 days after bm12.Kd.IE heart trans-
omC57BL/6 recipients 1week after transplantationwith DC- andB cell-depleted
transplantation; and H-2b Rag2/ recipients 5 weeks after bm12.Kd.IE heart
.Kd.IE heart transplantation are overlaid for comparison—shaded).
representative of two independent experiments resulting in n = 5 in each group
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Figure 3. Endothelial Expression of MHC
Class II Antigen
(A) C57BL/6 (blue) and bm12.kd.IE (red) endo-
thelial cells were cultured from neonatal car-
diomyocytes, with representative flow cytometric
overlay histograms confirming (top panels) upre-
gulated expression of CD105 and isolectin B4.
(B) Cultured C57BL/6 endothelial cells expressed
exclusively MHC class II I-Ab, whereas cultured
bm12.kd.IE endothelial cells expressed exclu-
sively MHC class II I-E antigens (lower panels:
shaded histograms isotype control antibody).
Immunofluorescent staining with anti-CD31
(endothelial) antibody and with either anti-I-E
or anti-I-Ab antibodies of cryostat sections of
bm12.Kd.IE heart allografts explanted 1 week
after transplantation into C57BL/6 recipients is
shown (scale bars, 20 mm).
Data are representative of one experiment (A) and
three independent experiments (B), with n = 5mice
per group.allorecognition was short lived (Figure 5A) and prolonged
upon transplantation of bm12.Kd.IE heart grafts into C57BL/6
Rag2/ recipients (Figure 5B). It was notable, however, that
ABM CD4 T cells proliferated weakly upon transfer into naive
C57BL/6 hosts (Figure 5A), suggesting a degree of cross-reac-
tivity to H-2b antigens. To avoid this, and to control for concerns
that the different responses observed with the various popu-
lations of transgenic T cells reflected differences in affinity of1236 Cell Reports 14, 1232–1245, February 9, 2016 ª2016 The AuthorsTCR for target epitope, heart allografts
from CB6F1 donors (BALB/c 3 C57BL/6
F1) were transplanted into bm12 recipi-
ents and direct-pathway responses
assessed by transfer of TCR75 CD4
T cells. TCR75 CD4 T cells do not recog-
nize I-Abm12 restricted antigen (Fig-
ure S1; Conlon et al., 2012b); hence, in
this model, I-Ab / H-2Kd-peptide target
epitope is only expressed on donor
APCs and TCR75 T cell division acts as
marker for exclusively direct-pathway re-
sponses (Figure 5C). In accord with the
ABM CD4 T cell transfer studies, TCR75
CD4 T cell division was only detectable
in the first week after transplantation
and abrogated in recipients of irradiated
hearts (Figure 5D). Similarly, depletion
of either donor B cells or DCs prior to
heart graft retrieval significantly reduced
the direct-pathway TCR75 CD4 T cell
response (Figure 5D).
In contrast to the bm12.Kd.IE to
C57BL/6 model, donor CB6F1 cells are
cleared rapidly by host (C57BL/6) NK
cell recognition (Figure 5E). However,
prolongation of direct-pathway TCR75
CD4 T cell recognition was only achieved
in recipients lacking both NK cells andCD4 T cells (Figure 5F), and the response at week 2 was still sub-
stantially weaker than that observed at week 1, presumably re-
flecting the expected half-life of DCs is at most a few weeks
(Merad et al., 2007; Merad andManz, 2009). Hence, the duration
of direct-pathway activation is normally limited by both innate
and adaptive alloimmune recognition of donor APCs, and even
when both are incapacitated, the short lifespan of the donor
APC fraction rapidly terminates the response.
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Late Allopeptide Presentation Shapes the Dynamics of
the Endogenous CD4 T Cell Alloresponse
The confirmation, from the above adoptive transfer experiments
of TCR75 CD4 T cells, that MHC class I allopeptide epitope is
expressed at late time points in recipients of chronically reject-
ing heart allografts raises the question how this late presenta-
tion influences dynamics of the response of the endogenous
alloreactive CD4 T cell population. To address this, H-2Kd-pep-
tide-specific host T cell responses were mapped by labeling
splenocytes from transplanted mice with Kd54-68 / I-A
b tetramers
using a similar approach to that described for CD4 T cell re-
sponses against conventional protein antigen (Tubo et al.,
2013). Following transplantation with a bm12.Kd.IE cardiac allo-
graft, H-2Kd allopeptide-specific CD4 T cells underwent typical
expansion, contraction, and memory phases (Figure 6A), but in
comparison to challenge with a BALB/c heart allograft (Fig-
ure 6A), the expansion phase was much more marked and
approximately 10,000-fold more cells persisted into the memory
phase. Similar levels of H-2Kd alloantigen are expressed on
BALB/c and bm12.Kd.IE cardiomyocytes (Figure S6); hence,
the increased number of H-2Kd-specific CD4 T cells at late
time points following challenge with a bm12.Kd.IE heart allo-
graft is presumably due to ongoing allopeptide presentation.
In support, a less-profound contraction in the allospecific CD4
T cell population occurred in C57BL/6 recipients of a BALB/c
heart allograft and that received anti-CD154 antibody at trans-
plantation (Figure 6B), and this late expansion in recipients of
chronically rejecting heart allografts correlated with continued
division of the H-2Kd allopeptide-specific CD4 T cell population
(Figure 6C).
Antigen persistence is associated with CD4 T cell exhaustion
and defective anamnestic responses (Crawford et al., 2014).
Surface phenotyping of the Kd54-68/I-A
b tetramerpos CD4 T cell
population revealed that the percentage of antigen-experienced
CD44hi CD4 T cells was comparable 5 weeks after transplanta-
tion with a BALB/c or bm12.Kd.IE heart allograft but that the an-
tigen-experienced CD4 T cells in recipients of a bm12.Kd.IE
heart graft were predominantly CD44hiCCR7loCD62Llo effector
memory, whereas those in BALB/c heart-grafted recipients
were more skewed toward CD44hiCCR7hiCD62Lhi central mem-
ory (Figure 6D). To assess the functional consequences of this
difference, T-cell-deficient Tcrbd/ C57BL/6 mice were recon-
stituted with CD4 T cells purified from recipients of bm12.Kd.IE
or BALB/c heart grafts and the reconstituted Tcrbd/ mice
then challenged with a C57BL/6 donor heart that expressed
H-2Kd as a transgene (B6.Kd; Honjo et al., 2004) while simulta-Figure 4. Persistent Indirect-Pathway CD4 T Cell Activation from Graft
(A) Indirect-pathway CD4 T cell responses against MHC class I alloantigen were as
T cells, adoptively transferred into C57BL/6 recipients at transplantation with a
inhibited TCR75 CD4 T cell division.
(B) Bone marrow chimeric recipients were created as depicted, by transferring
representative flow cytometry plots demonstrating H-2Kd expression in chimeric
(C) Heart allografts from bm12.Kd.IE, bm12.IE, or bm12.Kd.IE/bm12.IE bone m
TCR75 CD4 T cells (transferred at the time of, or 5 weeks after, transplantation)
(D) BALB/c heart allografts were transplanted into C57BL/6 recipients that were ei
TCR75 CD4 T cells (left panel) or TEa CD4 T cells (right), transferred at the times
*p < 0.05, **p < 0.01, and ***p < 0.001 (Mann-Whitney test in A, C, and D). Data are
(A, C, and D; mean and SEM of n = 5 mice per group).
1238 Cell Reports 14, 1232–1245, February 9, 2016 ª2016 The Authoneously receiving anti-CD154 mAb. We reasoned that only
established H-2Kd-specific memory CD4 T cells would be able
to provide co-stimulation-independent help for development of
anti-H-2Kd alloantibody responses against the B6.Kd graft (Con-
lon et al., 2012a). Whereas anti-H-2Kd alloantibody was not
observed in Tcrbd/ recipients reconstituted with CD4 T cells
from bm12.Kd-IE grafted mice, weak but consistent anti-H-2Kd
alloantibody responses developed in Tcrbd/ recipients recon-
stituted with CD4 T cells from BALB/c-grafted mice (Figure 6E),
despite the vastly reduced number of H-2Kd allopeptide-specific
CD4 T cells present in this latter group at late time points after
transplantation (Figure 6B). Thus, chronic allopeptide presen-
tation drives continual division of the responding alloreactive
CD4 T cell population, with persistence of a greatly expanded
population but with functional evidence of altered memory
development.
DISCUSSION
Transplantation is unique in that MHC alloantigen can be
recognized by host T cells by at least two distinct pathways.
Bymodifying the standard technique of transfer of CFSE-labeled
TCR-transgenic CD4 T cells, our experiments confirm that
direct-pathway CD4 T cell allorecognition is short lived and
limited by innate and/or adaptive alloimmune-mediated elim-
ination of donor APCs. We also detail that indirect-pathway re-
sponses to chronically rejecting allografts are heterogeneous
and vary according to target alloantigen, with responses against
MHC class II peptides also limited by rapid destruction of donor
hematopoietic cells.
Fundamental to our experimental approach was the design
of a transplant model wherein direct and indirect T cell allor-
esponses could be assessed simultaneously and in which pro-
liferation of a particular alloreactive T cell population when trans-
ferred at transplantation acted as control for the same population
transferred at later time points. Thus, interpretation of results
should not be confounded by potential differences in TCR affinity
between the various TCR-transgenic clones; such concerns are
further obviated by the development of additional models that
enabled H-2Kd-allopeptide-specific TCR75 CD4 T cells to act
either exclusively via the indirect pathway or exclusively via the
direct pathway. Additionally, to reconcile observations obtained
from adoptive transfer of TCR-transgenic CD4 T cells with events
occurring within the endogenous alloreactive CD4 T cell popula-
tion, we used synthetic MHC class II I-Ab/allopeptide tetrameric
complexes to assess host CD4 T cell responses against theParenchymal Expression of MHC Class I
sessed, as detailed in Figure 2, by quantifying division of CFSE-labeled TCR75
bm12.Kd.IE allograft; neither donor lethal irradiation nor donor DC depletion
bm12.Kd.IE bone marrow into lethally irradiated bm12.IE mice: lower panels,
mice on hematopoietic cells (splenic B cells).
arrow chimeric mice were transplanted into C57BL/6 recipients and division of
quantified.
ther left untreated or administered anti-CD154 at transplantation and division of
indicated, quantified.
representative of two independent experiments resulting in n = 5 in each group
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same dominant H-2Kd epitope as recognized by TCR75 CD4
T cells. This approach has been detailed recently for responses
against conventional protein antigen (Tubo et al., 2013), but our
studies revealed that the alloreactive CD4 T cell responses in the
chronic and acute rejection models differ profoundly. In chronic
rejection, less-profound contraction of the alloreactive CD4
T cell population occurred, with a markedly augmented mainte-
nance phase. This presumably reflects continual cell division
from failure to clear target allopeptide epitope, but whether this
was due to ongoing cell cycling of the original alloreactive pop-
ulation or to late recruitment of naive alloreactive CD4 T cells
(Lin et al., 2010) was not assessed.
Our findings raise the question whether the continued divi-
sion and expansion of class I allopeptide-specific CD4 T cells
contributes to progression of allograft vasculopathy. Our exper-
iments were not designed specifically to address this, and it is
plausible that chronically stimulated CD4 T cells are unable to
mediate allograft rejection, as suggested by our data demon-
strating that some aspects of allospecific CD4 T cell memory
are inhibited by the continual presence of target epitope.
Against this, preservation of limited anti-viral function has
been described for exhausted CD4 T cells (Yi et al., 2009),
and similarly, chronic salmonella infection is controlled by late
CD4 T cell responses (Nelson et al., 2013). Notwithstanding,
an intriguing possibility raised by our findings is that in
‘‘tolerant’’ recipients, the class I allopeptide-specific CD4
T cell population will be either static or dividing only minimally.
Although the technical challenges are daunting, one could
envisage that, in the future, tetramer characterization of the di-
vision profile of the responding alloreactive CD4 T cell popula-
tion may be used clinically to identify patients at risk of chronic
rejection or those in whom immunosuppression can be safely
discontinued.
What then are the implications of our findings for clinical
transplantation? It has been suggested that expression of
MHC class II is different within human organ allografts, in that
human endothelial cells upregulate MHC class II in response
to IFN-g, albeit levels are still lower than for MHC class I (Piotti
et al., 2014; Rose, 1998). However, it is also clear, as we
demonstrated in our model, that murine endothelium can ex-
press MHC class II, and although this expression is unable to
activate direct-pathway CD4 T cell responses (Kreisel et al.,Figure 5. Direct-Pathway CD4 T Cell Responses Are Short Lived and C
(A) Direct-pathway CD4 T cell responses were assessed in C57BL/6 recipients of
CD4 T cells, adoptively transferred at transplantation or 5 weeks later. Division of
comparison.
(B) Direct-pathway responses were prolonged in Rag2/ recipients of an unmo
(C) Direct-pathway CD4 T cell alloresponses were also assessed in bm12 recipie
TCR75 CD4 T cells. In this strain combination, TCR75 CD4 T cells do not recogniz
presented by I-Ab on donor cells.
(D) TCR75 CD4 T cell direct-pathway responses are short lived and significantly
B cells or DCs.
(E) Syngeneic C57BL/6 or allogeneic CB6F1 CD4 T cells were injected into either T
additionally lack NK cells (right panel) and the presence of circulating injected ce
(F) Direct-pathway responses were assessed as in (B) by quantifying division of TC
(week 2), transplantation of CB6F1 heart grafts into wild-type, NK cell-depleted,
*p < 0.05, **p < 0.01, and ***p < 0.001 (Mann-Whitney test in A, B, D, and F). Dat
group (A, B, D, and F; mean and SEM of n = 5 mice per group) and one experim
1240 Cell Reports 14, 1232–1245, February 9, 2016 ª2016 The Autho2004), it is essential for those responses to then autonomously
effect graft rejection (Grazia et al., 2004). Hence, available evi-
dence suggests that the parenchymal components of murine
and human organ allografts express MHC class II. Cultured hu-
man endothelial cells can activate CD4 T cell in vitro (Adams
et al., 1992; Hughes et al., 1990), although this has not been
a consistent finding (Ma and Pober, 1998). Whether the paren-
chymal expression of MHC class II alloantigen on human allo-
grafts can drive direct-pathway CD4 T cell activation has not
been tested and seems unlikely, because clinical studies report
this response to be short lived (Baker et al., 2001). This further
suggests that, despite concurrent administration of immuno-
suppression, donor hematopoietic cells are rapidly eliminated
in human recipients, and it is notable that the T cell response
against MHC class II alloantigen was similarly brief in our
BALB/c to C57BL/6 heart transplant model, in which acute
rejection was avoided by concurrent administration of anti-
CD154 antibody.
Irrespective of inter-species discrepancies in immune struc-
ture and function, our principal finding that murine indirect-
pathway CD4 T cell responses vary considerably according to
target alloantigen is likely to be relevant to human transplanta-
tion, albeit there may be differences in the alloantigen targeted
or in the constancy of expression of its epitope. Understanding
the relative timing and contribution of direct and indirect CD4
T cell alloresponses to allograft rejection has become all the
more important following the recent introduction of alloan-
tigen-specific regulatory T cell (T-reg cell) therapy to clinical
transplantation (Brunstein et al., 2011; Di Ianni et al., 2011; New-
ell et al., 2011; Trzonkowski et al., 2009; Wood et al., 2012). Our
results suggest that, for a particular recipient, the success of
alloantigen-specific T-reg cell therapy will be governed by
whether target epitope is expressed concurrently and provide
an explanation for why, in certain animal models, T-reg cells
with indirect allospecificity are more effective than those with
direct allospecificity in preventing chronic rejection (Joffre
et al., 2008; Tsang et al., 2008). T-reg cells with direct allo-
specificity are likely to be effective only if injected in the imme-
diate post-transplant period. Indirect-pathway T-reg cells hold
greater potential for administration at later time points after
transplantation as a means of controlling development of
chronic rejection, but the success of such an approach willurtailed by Innate and Adaptive Alloimmunity
bm12.Kd.IE cardiac allografts by quantifying division of I-Abm12-reactive ABM
ABM CD4 T cells following transfer into naive C57BL/6 recipients is shown for
dified bm12.Kd.IE heart allograft.
nts of a BALB/c 3 C57BL/6 F1 (CB6F1) heart allograft by adoptive transfer of
e recipient I-Abm12-restricted H-2Kd allopeptide but respond to H-2Kd-peptide
downregulated by lethal irradiation of the donor or depletion of either donor
- and B-cell-deficient C57BL/6Rag2/mice (left panel) or Rag2IL2rgmice that
lls (expressed as percentage of PBMCs) assessed by flow cytometry.
R75 CD4 T cells that were adoptively transferred at the time of, or 1 week after
or T-cell-deficient bm12 recipients.
a are representative of two independent experiments resulting in n = 5 in each
ent with n = 3 in each group (E).
rs
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require consideration of which indirect-pathway CD4 T cell
responses are active.
EXPERIMENTAL PROCEDURES
Animals
Wild-type (WT) C57BL/6 (B6; H-2b) and BALB/c (H-2d) and CB6F1 (C57BL/63
Balb/c F1 – H-2bd) mice were purchased from Charles River Laboratories.
Bm12 mice - B6(C)-H2-Ab1bm12/KhEgJ (H-2bm12), B6.CD11c-DTR (H-2b -
B6.FVB-Tg), BALB/c.CD11c-DTR (H-2d - C.FVB-Tg), and Tcrbd/ B6 (H-2b)
mice (Jung et al., 2002) were purchased from The Jackson Laboratory.
BALB/c.CD11c-DTR mice were crossed with B6 to obtain CB6F1 (H-2bd)
mice expressing the DTR gene (CB6F1.CD11c-DTR). Tcrbd/ B6 mice
were crossed with bm12 mice to create bm12-Tcrbd/ T-cell-deficient
mice. C57BL/6Rag2/mice (H-2b) were gifted by Prof. T. Rabbitts (University
of Cambridge). Rag2IL2rg (Song et al., 2010; H-2b Rag2/ lacking the IL-2 re-
ceptor g chain; NK cell deficient) was kindly gifted by Dr. Francesco Colucci
(University of Cambridge). C57BL/6 mice that lack expression of I-Ab but ex-
press surface I-E antigen on APCs due to I-Ea gene incorporation (ABOIE)
were gifted by Prof. C. Benoist (Joslin Diabetes Center; Le Meur et al.,
1985). C57BL/6-Tg(Kd)RPb mice (B6.Kd; Honjo et al., 2000) expressing
H-2Kd were gifted by Dr. R.P. Bucy (University of Alabama). Bm12.Kd.IE
mice were created in house by first crossing bm12 3 B6.Kd, selecting from
the offspring those expressing I-Abm12 and H-2Kd, but not I-Ab (bm12.Kd),
and then crossing them with ABOIE mice and selecting offspring expressing
I-Abm12, I-E, and H-2Kd, but not I-Ab. For TCR transgenic animals, Rag2/
TEa mice (H-2b; TEa), specific for I-Ab-restricted I-Ed52-68 peptide, were gifted
by Prof. A. Rudensky (University of Washington; Grubin et al., 1997); Rag1/
TCR75 mice (H-2b; TCR75), specific for I-Ab-restricted H-2Kd54-68 peptide,
were gifted by Prof. P. Bucy (University of Alabama; Honjo et al., 2004);
Rag2/ ABM mice (H-2b; ABM), I-Abm12 restricted, were gifted by Dr. T.
Crompton (Imperial College; Ba¨ckstro¨m et al., 1998); and Rag1/ Marilyn
mice (H-2b; Mar), specific for the I-Ab-restricted H-Y dby608–622 peptide,
were gifted by Dr. Di Scott (Imperial College; Lantz et al., 2000). Mice were
bred and maintained in specific-pathogen-free animal facilities, and all exper-
iments were approved by the UK Home Office under the Animals (Scientific
Procedures) Act 1986.
Generation of Bone Marrow Chimeras
To create chimeric mice that were CD11c-DTR+ transgenic only in bone
marrow cells, C57BL/6 mice were lethally irradiated (23 6.5 Gy) and reconsti-
tuted with 2 3 107 bone marrow cells from C57BL/6.CD11c-DTR mice. The
DCs in these mice remained susceptible to diphtheria toxin (DT) treatment,
but the mice were significantly more resistant to overall toxicity (Sapoznikov
and Jung, 2008). Bm12.Kd.IE mice with expression of class I H-2Kd restricted
to the hematopoietic compartment were generated by lethal irradiation of
bm12.IE mice and reconstituted with 2 3 107 bone marrow cells fromFigure 6. Late Allopeptide Presentation Shapes the Dynamics of the E
(A) The endogenous H-2Kd54-68 allopeptide-specific splenic CD4 T cell subset in
labeling with H-2Kd54–68/I-A
b tetramers: representative flow cytometry plots of bi
panels) H-2Kd54–68/I-A
b tetramer (experimental) or to control I-Ab tetramer bou
quantification of absolute numbers of tetramer-positive cells present in C57BL/6
allografts (right panel).
(B) Prevention of acute rejection by anti-CD154 mAb treatment of C57BL/6 rec
specific CD4 T cells 7 weeks after transplant.
(C) H-2Kd-allopeptide-specific CD4 T cells in cell cycle, identified by Ki-67 labelin
positive cells.
(D) Within the antigen-experienced CD44hi tetramer-positive CD4 T cell popula
effector (bottom right) memory T cells were quantified (gating strategy shown on
bm12.Kd.IE heart allografts into C57BL/6 recipients.
(E) Anti H-2Kd IgG alloantibody responses to a B6.Kd heart allograft in Tcrbd/
T cells purified from C57BL/6 recipients 5 weeks after transplantation with BALB
*p < 0.05, **p < 0.01, and ***p < 0.001 (two-way ANOVA in A and E and Mann-Wh
group (A–C, and E; mean and SEM of n = 4 mice per group) and of two indepen
1242 Cell Reports 14, 1232–1245, February 9, 2016 ª2016 The Authobm12.Kd.IE mice. Chimerism was confirmed by flow cytometric analysis of
PBMCs at least 4 weeks following reconstitution.
Skin and Heterotopic Cardiac Transplantation
Full-thickness tail skin was sutured as 1 cm2 grafts onto the recipient’s back.
Vascularized cardiac allografts were transplanted intra-abdominally using the
technique of Corry and colleagues (Corry et al., 1973). Heart graft rejection was
defined as cessation of palpable myocardial contraction, confirmed at explant
for histology. In certain experiments, recipients of BALB/c heart allografts were
injected i.p. with 500 mg anti-CD154 mAb (clone MR-1; BE0017-1; Bio X Cell)
on days 2, 0, 2, and 4 in relation to transplantation, a protocol that prevents
acute allograft rejection but that results in development of chronic allograft
vasculopathy.
In Vivo Depletion and Transfer of Donor and Recipient Leukocyte
Subsets
Hematopoietic cells were depleted as previously described (I.G.H., J.M.A.,
S.J.F. Harper, E. Wlodek, M.C.N., M.S.Q., R.M., K.S.-P., E.M.B., J.A.B.,
M.R. Clatworthy, T.M.C., and G.J.P., unpublished data) by lethal irradiation (2
3 6.5 Gy) of donor mice 7 days before heart allograft procurement. B6.CD11c-
DTR, BALB/c.CD11c-DTR, and CB6F1.CD11c-DTR donors and C57BL/6 (BL/
6.CD11cDTR) chimeric heart graft recipients were treated with i.p. 32 ng/g DT
(List Biological Laboratories) on days5,3, and1 (donors) or thrice weekly
in recipients. To deplete CD4 T cells, mice were treated with 1 mg i.p. anti-
CD4-depleting mAb (rat IgG2b; clone YTS 191.1; hybridoma from European
Collection of Cell Cultures; Health Protection Agency; Porton Down U.) on
days 5, 3, and +1 relative to transplantation and weekly thereafter. To
deplete B cells, mice were treated with 250 mg i.p. depleting anti-CD20 mAb
(18B12; IgG2a gifted by Cherie Butts, Biogen Idec) on day 7 and, for recipi-
ents, fortnightly thereafter. To deplete NK cells, mice were treated with 0.5 mg
i.p. depleting anti-NK1.1mAb (mouse 1gG2a; clone PK13 – hybridoma; ATCC-
LGC Standards Partnership) on days2, 0, and +2 and weekly thereafter. Cell
depletion was confirmed by flow cytometry.
In certain experiments, Rag2/ and/or Rag2IL2rg mice were adoptively
transferred i.v. 1 3 107 donor CD4 T cells (purified with anti-mouse CD4 Mi-
croBeads; Miltenyi Biotec) or 1 3 107 donor B cells (purified with anti-mouse
CD19 MicroBeads) using an autoMACS Separator (Miltenyi Biotec).
In another experiment, 1 3 107 memory CD4 T cells were purified from re-
cipients of bm12.Kd.IE or BALB/c heart grafts 6 weeks after transplant using
magnetic bead separation as above and transferred into naive C57BL/6
Tcrbd/ mice that were subsequently challenged with B6.Kd cardiac
allografts.
Quantification of Circulating Antibodies
Serum samples were collected from experimental mice at intervals and
analyzed for the presence of anti–H-2Kd IgG alloantibody by ELISA as previ-
ously described (Conlon et al., 2012b). In anti-I-E alloantibody quantified byndogenous CD4 T Cell Alloresponse
C57BL/6 recipients of bm12.Kd.IE or BALB/c heart allografts was identified by
nding of splenocytes purified from bm12.Kd.IE heart grafted recipients to (left
nd with human CLIP87–101 (class-II-associated invariant chain peptide) and
recipients at weekly intervals after transplant of bm12.Kd.IE or BALB/c heart
ipients of a BALB/c heart allograft augments numbers of H-2Kd-allopeptide-
g 5 weeks after transplantation and expressed as percentage of total tetramer-
tion (top left panel), CCR7hiCD62Lhi central (bottom left) and CCR7loCD62Llo
representative flow cytometry plot) 7 weeks after transplantation of BALB/c or
recipients, treated with anti-CD154 mAb and reconstituted with splenic CD4
/c or bm12.Kd.IE heart allografts.
itney test in B–D). Data are representative of one experiment with n = 4 in each
dent experiments with a total of n = 5 in each group (D).
rs
flow cytometry, briefly, serum was serially diluted and incubated with ABOIE
bone-marrow-derived DCs (BMDCs) (prepared as previously described; Siva-
ganesh et al., 2013); bound alloantibody was detected with FITC-conjugated
anti-mouse IgG mAb (STAR 70; Serotec) and analyzed. The geometric
mean-channel fluorescence was plotted against dilution, and the AUC was
calculated as for H-2Kd alloantibody.
Circulating autoantibody levels were determined by HEp-2 indirect immuno-
fluorescence as previously described (Callaghan et al., 2012).
Mouse Heart Homogenization and Endothelial Cell Culture
Mouse hearts were finely diced, digested with collagenase (1 mg/ml collage-
nase A [Roche], 1 mg/ml DNase1 [Roche], and 2% FCS [Sigma-Aldrich] in
DMEM) and passed through a 40-mm nylon strainer to yield a single-cell
suspension.
For endothelial cell culture, 10- to 14-day neonatal hearts were homoge-
nized as above and endothelial cells isolated by incubating with biotin-conju-
gated antibodies against CD31 (clone MEC 13.3; BD PharMingen), CD105
(clone MJ7/18; BioLegend), and isolectin B4 (clone B-1205; Vector) followed
by anti-biotin MicroBeads and purified using an autoMACS Separator (both
Miltenyi Biotec). Endothelial cells were cultured overnight in growth medium
(HEPES-buffered DMEM with 10% FCS, 100 IU/ml penicillin-streptomycin,
and 2 mM L-glutamine; Life Technologies) in tissue culture flasks (Nunc;
Thermo Scientific) pre-coated with 1% gelatin (Sigma-Aldrich) in PBS. Non-
adherent cells were removed and endothelial cell growth factor (E9640;
Sigma-Aldrich) added to the culture medium. Cells were passaged by incu-
bation with trypsin-EDTA solution (Life Technologies) at 37C until cells
detached.
Histopathology and Immunohistology
Splenic GCs were identified by double-labeling 7 mm cryostat sections with rat
anti-mouse B220 (clone RA3-6B2; BD PharMingen) detected with Cy3-conju-
gated goat anti-rat IgG (clone 112-165-143; Jackson ImmunoResearch Labo-
ratories) and biotinylated rat anti-mouse GL-7 (clone Gl-7; E-Bioscience) de-
tected with Cy2-streptavidin (Jackson ImmunoResearch Laboratories).
Endothelial MHC class II expression was detected in donor heart 7 mm
cryostat sections by double labeling with rat anti-mouse CD31 (clone MEC
13.3; BD Pharmingen) detected with Cy3-conjugated goat anti-rat IgG
and FITC-conjugated rat anti-mouse I-E (clone 14-4-45; BD Pharmingen)
followed by FITC-conjugated rat anti-mouse I-Ab (clone AF6-120.11; BD
PharMingen). Sections were counterstained with 20% Harris’ hematoxylin
(Sigma-Aldrich).
Cardiac allograft vasculopathy was assessed on elastin van Gieson-stained
paraffin sections by morphometric analysis as previously described (Calla-
ghan et al., 2012). All elastin-positive vessels in each section were evaluated,
with approximately ten vessels/heart analyzed.
Flow Cytometry
APC-CD4 (clone GK1.5), PE-Cy7-CD4 (clone GK1.5), PE-CD8 (clone 53-6.7),
PercP-CD8 (clone 53-6.7), APC-Cy7-CD11b (clone MI/70), PE-CD11c (clone
HL3), FITC-CD11c (clone HL3), PE-CD19 (clone 1D3), APC-CD19 (clone
1D3), PercP-CD25 (clone PC61), APC-CD44 (clone IM7), APC-CD62L
(clone MEL-14), FITC-CD69 (clone H1.2F3), biotin-CD105 (clone MJ7/18),
biotin-isolectin B4 (clone B-1205), FITC-I-E (clone 14-4-45), FITC-I-Ab (clone
AF6-120.11), biotin-NK1.1 (clone PK136), APC-Cy7-CD90.1/Thy1.1 (clone
OX-7), biotin-Va2 (clone B20.1), PE-Vb6 (clone RR4-7), PE-Vb8 (clone OX-7),
PE-Vb8.3 (clone 1B3.3), biotin-YA-e (clone YA-e), and PE-Kd (clone SF1-1)
were purchased from BD PharMingen. Peripheral blood (erythrocyte-depleted
by 0.17 M NH4Cl lysis) and splenic single-cell suspensions were blocked with
anti-mouse CD16/CD32 (clone 2.4G2) before staining with the relevant Abs
and dead cell exclusion dye 7-aminoactinomycin (both from BD PharMingen).
Biotinylated Abs were detected by allophycocyanin-conjugated streptavidin
(Invitrogen), and cells were analyzed on a FACSCanto II flow cytometer with
FACSDiva software (Becton Dickinson).
For subsequent intracellular antigen detection, surface-labeled cells were
fixed and permeabilized using the Cytofix/Cytoperm kit according tomanufac-
turer’s instructions (BD Biosciences) and incubated with antibodies to Ki67
(clone B56; BD PharMingen).Cell RFor tetramer labeling, spleen single-cell suspensions in FACS buffer were
blocked with anti-CD16/CD32 and incubated with PE-conjugated MHC class
II I-Ab tetramers presenting MHC class I Kd peptide 54-68 (QEGPEYWEEQT
QRAK), kindly gifted by the NIH Core Tetramer facility. After 1 hr at 37C, cells
were washed and tetramer-bound cells were enriched using anti-PE microbe-
ads (Moon et al., 2007; Tubo et al., 2013; Miltenyi Biotech) and an Automacs
separator. Additional cell surface antigens were then labeled for flow cytome-
try as above, and antigen-specific CD4 T cells were identified as tetramer- and
CD4-positive but negative for CD19, CD11c, CD11b, and CD8. Antigen-spe-
cific CD4 T cells were enumerated after MACS separation by Trucount analysis
according to manufacturer’s instructions (BD Biosciences).
CFSE CD4 T Cell Proliferation
Proliferation of splenocytes from TCR75, TEa, ABM, andMar mice were deter-
mined by CFSE-labeled cell division at day 7 following adoptive transfer as
previously described (Conlon et al., 2012b) using PE-Cy7-conjugated anti-
CD4 plus APC-Cy7-conjugated anti-CD90.1/Thy 1.1 (congenic marker) to
identify TCR75, PE-conjugated anti-Vb8 to identify ABM, biotin-conjugated
Va2 and PE-conjugated anti-Vb6 to identify Tea, and PE-conjugated anti-
Vb8.3 to identify Mar cells. CFSE-labeled splenocytes were transferred either
early, at transplantation, or late on day 28 after transplant (to measure CD4
T cell alloresponses during the first and fifth week, respectively). In one exper-
iment, proliferation of TEa splenocytes was examined late after transfer of 53
106 donor bm12.Kd.IE BMDCs (generated as described above). Proliferation
was quantified using FlowJo (Treestar) as the percentage of cells from the orig-
inal parent population that had undergone division.
Statistical Analysis
Data were presented asmean ±SEMwhere appropriate. Mann-Whitney U test
was used for analysis of nonparametric data. Two-way ANOVA was employed
for comparison of anti-H-2Kd, anti-I-E, and anti-nuclear antibody levels. Graft
survival was depicted using Kaplan-Meier analysis and groups compared by
log rank (Mantel-Cox) testing. Analysis was conducted using GraphPad 4
(Graph-Pad Software). Values of p < 0.05 were considered significant.
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